Bridge Biotherapeutics to Present Interim Clinical Data from

The abstract suggests that BBT-176 has shown its capability of inducing clinical tumor responses in EGFR triple mutation-containing patients Further exploration of the drug

Related Keywords

China , Vienna , Wien , Austria , Seongnam , Kyonggi Do , South Korea , South Korean , Republic Of Korea , Korea , , Ministry Of Health , Yonsei University College Of Medicine , Korea Drug Development Fund , Yonsei University College Of Medicinesession Discussant , Biotherapeutics Inc , Dana Farber Cancer Institute , Korea Research Institute Of Chemical Technology , Bridge Biotherapeutics Inc , Ministry Of Science , International Association , Lung Cancer , Sun Min Lim , Yonsei University College , Presentation Informationtitle , Session Title , Overcoming Resistance , Session Number , Medicinesession Discussant , Dana Farber Cancer , Korea Research Institute , Chemical Technology , Bridge , Biotherapeutic , Ealth Press Release ,